Table 1 Comparison of patient characteristics across seven clusters based on model 1.
Cluster 1 (n = 41) PR3-ANCA (+) | Cluster 2 (n = 8) ANCA (−) | Cluster 3 (n = 47) MPO-ANCA (+) ENT | Cluster 4 (n = 36) MPO-ANCA (+) Cutaneous | Cluster 5 (n = 256) MPO-ANCA (+) Renal | Cluster 6 (n = 33) MPO-ANCA (+) Non-renal | Cluster 7 (n = 6) MPO-ANCA (+) ENT with cutaneous | |
|---|---|---|---|---|---|---|---|
Female/male | 22/19 | 3/5 | 28/19 | 22/14 | 141/115 | 23/10 | 4/2 |
Age (years) | 63 (58–74) | 64 (60–73) | 72 (62–79) | 69 (59–76) | 73 (65–79) | 75 (68–80) | 71 (62–75) |
GPA (%) | 34 (83) | 2 (25) | 34 (72) | 2 (6) | 11 (4) | 1 (3) | 2 (33) |
MPA (%) | 3 (7) | 2 (25) | 12 (26) | 25 (69) | 218 (85) | 7 (21) | 3 (50) |
Unclassifiable (%) | 4 (10) | 4 (50) | 1 (2) | 9 (25) | 27 (11) | 25 (76) | 1 (17) |
MPO-ANCA (%) | 2 (5) | 0 | 47 (100) | 36 (100) | 256 (100) | 33 (100) | 6 (100) |
PR3-ANCA (%) | 34 (82.9) | 0 | 4 (8.5) | 1 (2.8) | 7 (2.7) | 0 | 1 (16.7) |
Serum creatinine (mg/dL) | 0.79 (0.6–1.2) | 0.64 (0.57–0.71) | 1.2 (0.83–3.5) | 0.96 (0.66–19) | 2.1 (0.97–4.0) | 0.67 (0.57–0.82) | 0.99 (0.75–1.6) |
CRP (mg/dL) | 3.9 (1.2–11) | 4.3 (1.2–11) | 11 (5.6–15) | 7.4 (2.6–12) | 6.5 (1.4–12) | 8.1 (4.6–12) | 9.3 (0.44–16.3) |
ILD (%) | 3 (7) | 3 (38) | 12 (26) | 8 (22) | 126 (49) | 28 (85) | 5 (83) |
General (%) | 26 (63) | 8 (100) | 37 (79) | 29 (81) | 155 (61) | 25 (76) | 4 (67) |
Cutaneous (%) | 4 (10) | 4 (50) | 0 | 36 (100) | 8 (3) | 1 (3) | 6 (100) |
Mucous membranes/eyes (%) | 15 (37) | 1 (13) | 14 (30) | 2 (6) | 16 (6) | 2 (6) | 0 |
Ear nose and throat (%) | 33 (80) | 2 (25) | 47 (100) | 1 (3) | 0 | 0 | 6 (100) |
Chest (%) | 18 (44) | 2 (25) | 29 (62) | 13 (36) | 98 (38) | 9 (27) | 3 (50) |
Cardiovascular (%) | 3 (7) | 0 | 3 (6) | 3 (8) | 25 (10) | 0 | 0 |
Abdominal (%) | 1 (2) | 0 | 0 | 0 | 3 (1) | 0 | 0 |
Renal (%) | 22 (54) | 1 (13) | 37 (79) | 28 (78) | 256 (100) | 0 | 4 (67) |
Nervous system (%) | 12 (29) | 7 (88) | 21 (45) | 21 (58) | 62 (24) | 9 (27) | 4 (67) |
